India approves AstraZeneca and local Covid vaccines, rollout in weeks

Published January 3, 2021
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters

India’s drugs regulator on Sunday gave final approval for the emergency use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.

The world’s second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech’s Covaxin administered under stricter conditions given that no efficacy data has been released for it.

The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42 per cent, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response”, said Drugs Controller General of India VG Somani.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded Covishield, while Bharat Biotech has teamed up with the government run Indian Council of Medical Research.

“Vaccines of Serum [Institute of India] and Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement at a press conference. Somani did not take questions.

Both vaccines will be administered in two doses and stored at two to eight degrees Celsius, he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.

Somani explained that the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains”.

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.

“All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “Covishield, India’s first Covid-19 vaccine, is approved, safe, effective and ready to roll out in the coming weeks.”

Opinion

Shared city
26 Jan 2021

Shared city

Karachi is not a city ‘created by everybody’.
Back to governance
Updated 25 Jan 2021

Back to governance

While PDM has continued efforts to mount political pressure, it has been unable to force a crisis to challenge the PTI government.

Editorial

Pakistan-US ties
Updated 26 Jan 2021

Pakistan-US ties

The US remains the world’s most powerful country, one Pakistan cannot afford to ignore.
26 Jan 2021

NAB not impartial

NAB CHAIRMAN retired justice Javed Iqbal has claimed that his organisation is an unbiased anti white-collar-crime...
26 Jan 2021

Pakistan-South Africa series

IN what is seen as a rare instance, Pakistan start as the underdogs on their home turf when they take on South ...
Updated 25 Jan 2021

Where the buck stops

The rights to due process and security of person are accorded to every individual in this country.
25 Jan 2021

PPP’s plan?

THE PDM faces a fresh crisis as the PPP takes a conspicuously soft position on the long march. While the PDM talks ...
25 Jan 2021

Forward guidance

THE State Bank has taken the unusual step of issuing a forward guidance in its latest monetary policy statement to...